-
Behavioural scienceAdherence and persistence confirms
Semaglutide and tirzepatide prescriptions in adults with obesity often end within a year
Of 9,189 adults with obesity but no diabetes starting semaglutide or tirzepatide, 18.6% had coverage for 336 days or more.
Peer-reviewed -
Behavioural scienceAlcohol and drug use refines
Accidental overdose admissions in New South Wales and later premature death by cause
Among 14,036 people hospitalised for accidental overdose in New South Wales, deaths ran at 3.5 times the expected rate.
Peer-reviewed -
Data, models and systemsForecasts and their record refines
Ensemble models of expected US mortality were more accurate than single models
Using weekly US deaths for 2008–2024, ensemble models gave more accurate expected mortality, with better coverage, than single models.
Peer-reviewed -
Data, models and systemsWhat linked data reveals refines
Hepatitis C treatment in one US state's Medicaid rose as access restrictions ended
Hepatitis C treatment initiation in one US state's Medicaid rose as restrictions ended, but peaked at 23% for 2020 diagnoses.
Peer-reviewed -
Data, models and systemsForecasts and their record new
People who inject drugs in the US: projected deaths, infections and costs, 2025-2034
A US microsimulation projects 487 249 deaths from injection drug use and $565 billion in healthcare costs over 2025–2034.
Peer-reviewed -
Behavioural scienceDiet, exercise and sleep new
GLP-1/GIP use in US adults rose to 12% by 2025, a third via non-traditional access
GLP-1/GIP use rose from 8.2% to 12.0% of US adults in 18 months, led by weight-loss use.
Preprint · not peer-reviewed -
Behavioural scienceInfection and pandemics refines
Injection-schedule adherence to long-acting cabotegravir plus rilpivirine in Spain
Among 3280 virologically suppressed adults in Spain, 70.4% received every evaluable injection within ±7 days; 0.7% had suboptimal adherence.
Peer-reviewed -
Behavioural scienceInfection and pandemics refines
Antibiotic use in patients hospitalised for COVID-19 across 64 countries, 2020 to 2023
Of 451,291 patients hospitalised for COVID-19 in 64 countries, 341,125 received antibiotics, mostly empirical WHO 'Watch' drugs.
Peer-reviewed -
Behavioural scienceSmoking and vaping new
Nicotine pouch use in British quit attempts rose 2021-2026, notably among 18-24s and men
Among British adults trying to stop smoking, pouch use nearly tripled to 6.7%, with an uncertain adjusted link to quitting.
Preprint · not peer-reviewed -
Behavioural scienceSmoking and vaping refines
Switching from cigarettes to e-cigarettes and human biomarkers of toxicant exposure
Complete switching from cigarettes to e-cigarettes was linked to lower levels of all ten pooled toxicant exposure biomarkers.
Peer-reviewed -
Behavioural scienceAlcohol and drug use new
Medetomidine appeared in about a quarter of Southern California fentanyl samples by 2026
Medetomidine was first detected in Southern California fentanyl in May 2025 and was present in about 25% by August 2026.
Preprint · not peer-reviewed -
Data, models and systemsHealth systems and access refines
Alcohol screening in US health care rarely leads to brief intervention for heavy drinkers
Most US adults in health care were asked about drinking, but only 4% of heavy drinkers reported a brief intervention.
Peer-reviewed
